Merck shares results for Keytruda in cervical cancer treatment

Betsy Goodfellow | March 18, 2024 | News story | Research and Development Merck, Oncology, cervical cancer, keytruda, women's health 

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, which investigates Keytruda in combination with chemoradiotherapy for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival in this indication, with the drug’s safety profile remaining consistent with previously observed safety information and no new safety signals being identified.

It is expected that the full results will be presented at an upcoming medical meeting as well as being shared with the relevant global regulatory authorities.

Dr Gursel Aktan, vice president, global clinical development at Merck Research Laboratories, commented: “This is the first phase 3 trial in which an immunotherapy-based regimen has shown a statistically significant and clinically meaningful improvement in overall survival compared to chemoradiotherapy alone. Building on the positive progression-free survival findings from this study, these results underscore our commitment to exploring the role of Keytruda across different types of cancers in earlier stages of disease, where there is a greater potential for better outcomes.”

Betsy Goodfellow

Related Content

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …

An overview of women’s health in 2024

Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues …

FDA approves Merck’s Winrevair for PAH treatment

Merck, known as MSD outside of the US and Canada, has announced that the US …

Latest content